<DOC>
	<DOCNO>NCT02114177</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety treatment regimen 12 week 8 week simeprevir combination sofosbuvir chronic hepatitis C virus ( HCV ) genotype 1 infect men woman without cirrhosis HCV treatment-na√Øve treatment-experienced .</brief_summary>
	<brief_title>Efficacy Safety Study Simeprevir Combination With Sofosbuvir Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis</brief_title>
	<detailed_description>This randomize ( study medication assign chance ) , open-label ( people know identity intervention ) , multicenter study . The study consist screen phase 6 week , open-label treatment phase 8 week 12 week , post-treatment follow phase 24 week end treatment . Approximately 300 participant randomly allocate 1:1 ratio receive 150 mg simeprevir combination 400 mg sofosbuvir daily either 12 week ( Arm 1 ) 8 week ( Arm 2 ) . Safety evaluation include assessment adverse event , clinical laboratory test , vital sign , physical examination . The maximum study duration participant approximately 42 week .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Hepatitis C virus ( HCV ) genotype 1a 1b infection confirm randomization Documentation presence absence NS3 Q80K polymorphism HCV genotype 1a infected participant randomization Documentation IL28B genotype randomization HCV ribonucleic acid level great 10,000 IU/mL screening Treatmentexperienced participant must least 1 documented previous course interferonbased regimen without ribavirin Absence cirrhosis participant Evidence clinical hepatic decompensation ( history current evidence ascites , bleed varix hepatic encephalopathy ) Infection/coinfection HCV nongenotype 1a 1b Coinfection human immunodeficiency virus ( HIV ) type 1 type 2 ( HIV1 HIV2 ) ( positive HIV1 HIV2 antibodies test screen ) Coinfection hepatitisB virus ( hepatitisBsurfaceantigen positive ) Previously treat direct act antiHCV agent ( approved investigational ) chronic HCV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Hepatitis C Virus Infection</keyword>
	<keyword>Simeprevir</keyword>
	<keyword>Sofosbuvir</keyword>
	<keyword>HCV</keyword>
	<keyword>Cirrhosis</keyword>
</DOC>